Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity

Journal of Medicinal Chemistry

Volumn 45, Issue 21, 2002, Pages 4706-4715

  Brady, Stephen F ^a   Pawluczyk, Joseph M ^a   Lumma, Patricia K ^a   Feng, Dong Mei ^a   Wai, Jenny M ^a   Jones, Raymond ^a   DeFeo Jones, Deborah ^a   Wong, Bradley K ^a   Miller Stein, Cynthia ^a   Lin, Jiunn H ^a   Oliff, Allen ^a,b   Freidinger, Roger M ^a   Garsky, Victor M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PIPERAZINEDIONE; PRODRUG; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DERIVATIZATION; DRUG DESIGN; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; PROSTATE CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PRODRUGS; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0037057580     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020139f     Document Type: Article

References (28)

1. Frydenberg, M.; Stricker, P. D.; Kaye, K. W. Prostate cancer diagnosis and management. Lancet 1997, 349, 1681-1687.
2. Beedassy, A.; Cardi, G. Chemotherapy in advanced prostate cancer. Semin. Oncol. 1999, 26 (4), 428-438.
3. Raghavan, D.; Koczwara, B.; Javis, M. Evolving strategies of chemotherapy for advanced prostate cancer. Eur. J. Cancer 1997, 33, 566-574.
4. DeFeo-Jones, D.; Garsky, V. M.; Wong, B. K.; Feng, D.-M.; Boylar, T.; Haskell, K.; Kiefer, D. M.; Leander, K.; McAvoy, E.; Lumma, P.; Wai, J.; Senderak, E. T.; Motzel, S. L.; Keenan, K.; Van Zwieten, M.; Lin, J. H.; Freidinger, R. M.; Huff, J. R.; Oliff, A.; Jones, R. E. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat. Med. 2000, 6, 1248-1252.
5. Kahn, S. R.; Denmeade, S. R. In vivo Activity of a PSA-Activated Doxorubicin Prodrug Against PSA-Producing Human Prostate Cancer Xenografts. Prostate 2000, 45, 80-83.
6. Jakobsen, C. M.; Denmeade, S. R.; Isaacs, J. T.; Gady, A.; Olsen, C. E.; Christensen, S. B. Design, Synthesis, and Pharmacological Evaluation of Thapsigargin Analogues for Targeting Apoptosis to Prostatic Cancer Cells. J. Med. Chem. 2001, 44, 4696-4703.
7. Garsky, V. M.; Lumma, P. K.; Feng, D.-M.; Wai, J.; Ramjit, H. G.; Sardana, M. K.; Oliff, A.; Jones, R. E.; DeFeo-Jones, D.; Freidinger, R. M. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy. J. Med. Chem. 2001, 44, 4216-4224.
8. Lilja, H. A Kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest. 1985, 76, 1899-1903.
9. Lilja, H.; Christensson, A.; Dahlen, U.; Matikainen, M.; Nilsson, O.; Pettersson, K.; Lovgren, T. Prostate-specific antigen in serum occurs predominantly in complex with alpha1-antichymotrypsin. Clin. Chem. 1991, 37, 1618-1625.
10. Otto, A.; Bar, J.; Birkenmeier, G. Prostate-specific antigen forms complexes with human alpha2-macroglobulin and binds to the alpha2-macroglobulin/LDL receptor related protein. J. Urol. 1998, 159, 297-303.
11. For details on the scope of this investigation, see: Brady, S. F.; Feng, D.-M.; Garsky, V. M. Conjugates Useful in the Treatment of Prostate Cancer. U.S. Patent 6,174,858, 2001.
12. Barnett, C. J.; Cullinan, G. J.; Gerzon, K.; Hoying, R. C.; Jones, W. E.; Newlon, W. M.; Poore, G. A.; Robison, R. L.; Sweeney, M. J.; Todd, G. C. Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate. J. Med. Chem. 1978, 21, 88-96.
13. Conrad, R. A.; Cullinan, G. J.; Gerzon, K.; Poore, G. A. Structure-Activity relationships of dimeric Catharanthus alkaloids. 2. Experimental antitumor activities of N-substituted deacetylvin-blastine amide (vindesine) sulfates. J. Med. Chem. 1979, 22, 391-400.
14. Pearce, H. L. Medicinal chemistry of bisindole alkaloids from Catharanthus. The Alkaloids 1990, 37, 145-204.
15. Trouet, A. B. L.; Hannart, J. A. A.; Rao, K. S. B. Vinblastine-23-oyl Amino Acid Derivatives for Use as Antitumor Agents. U.S. Patent 4,388,305, 1981.
16. Bhushana Rao, K. S. P.; Collard, M.-P.; Trouet, A. Vinca-23-oyl amino acid derivatives: as new anticancer agents (Review). Cancer Res. 1985, 5, 379-386.
17. Laguzza, B. C.; Nichols, C. L.; Briggs, S. L.; Cullinan, G. J.; Johnson, D. A.; Starling, J. J.; Baker, A. L.; Bumol, T. F.; Corvalan, J. R. F. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: Design, preparation, and representative in vivo activity. J. Med. Chem. 1989, 32, 548-555.
18. Bumol, T. F.; Parrish, J.; DeHerdt, S. V.; Spearman, M. E.; Pohland, R.; Borowitz, M. J.; Briggs, S. L.; Baker, A. L.; Marder, P.; Apelgren, L. D. In Breast Cancer; R. L. Ceriani, Ed.; Plenum Press: New York, 1987; pp 205-215.
19. Bhushana Rao, K. S. P.; Hannart, J. A.; Trouet, A. Vinblastine-C4 alkyl maleoyl and amino acid maleoyl derivatives: I. Chemistry and physicochemical data. Anticancer Res. 1989, 9, 619-624.
20. Collard, M.-P.; Bhushana Rao, K. S. P.; Trouet, A. Vinblastine-C4 alkyl maleoyl and amino acid maleoyl derivatives: II. Experimental antitumor activity against leukemias and human tumor xenografts. Anticancer Res. 1989, 9, 625-630.
21. Bhushana Rao, K. S. P.; Collard, M.-P.; Cornet, J.; Trouet, A. Vinblastine-C4 alkyl maleoyl and amino acid maleoyl derivatives: III. Experimental antitumor activities oflactosaminated serum albumin conjugates. Anticancer Res. 1989, 9, 973-980.
22. Owellen, R. J.; Donigian, D. W.; Hartke, C. A.; Hains, F. O. Correlation of biological data with physicochemical properties among the vinca alkaloids and their congeners. Biochem. Pharmacol. 1977, 26, 1213-12.
23. Hofle, G.; Steglich, W.; Vorbruggen, H. 4-Dialkylaminopyridines as highly active acylation catalysts. Angew. Chem., Int. Ed. Engl. 1978, 17, 7, 569-583.
24. DeFeo-Jones, D.; Brady, S. F.; Feng, D.-M.; Wong, B. K.; Bolyar, T.; Haskell, K.; Kiefer, D. M.; Leander, K.; McAvoy, E.; Lumma, P.; Pawluczyk, J. M.; Wai, J.; Motzel, S. L.; Keenan, K.; Van Zwieten, M.; Lin, J. H.; Garsky, V. M.; Freidinger, R.; Oliff, A.; Jones, R. E. A prostate specific antigen (PSA) activated vinblastine prodrug selectively kills PSA secreting cells in vivo. Molecular Cancer Therapeutics 2002, 1, 451-459.
25. Field, G. B.; Noble, R. L. Solid-phase peptide synthesis utilizing 9-fluorenylmethoxy-carbonyl amino acids. Int. J. Peptide Prot. Res. 1990, 35, 161-214.
26. Beyermann, M.; Bienert, M.; Niedrich, H.; Carpino, L. A.; Sadat-Aalee, D. Rapid continuous peptide synthesis via Fmoc amino acid chloride coupling and 4-(aminomethyl)piperidine deblocking. J. Org. Chem. 1990, 55, 721-728.
27. Stewart, D. E.; Sarkar, A.; Wampler, J. E. Occurrence and role of cis peptide bonds in protein structures. J. Mol. Biol. 1990. 214, 253-260.
28. Ramachandran, G. N.; Mitra, A. K. An Explanation for the rare occurrence of cis peptide units in proteins and polypeptides. J. Mol. Biol. 1976, 107, 85-92.